Capital with conviction. Science with purpose.

KVDOS Capital

Quant &
Algo

Quantitative strategies and algorithmic execution across public markets, digital assets, and derivatives. Systematic investing driven by proprietary signal generation, data-driven models, and disciplined risk management.

QNT.01
Systematic Strategies
Momentum, mean-reversion, and statistical arbitrage across equities, crypto, commodities, and volatility surfaces.
QNT.02
Execution Infrastructure
Low-latency routing, smart order execution, and transaction cost analysis across traditional and digital asset venues.
QNT.03
Risk Management
Real-time portfolio monitoring, drawdown controls, and cross-asset correlation management across all active strategies.
QNT.04
Signal Research
Alternative data sourcing, NLP-driven sentiment analysis, and ML signal validation across macro, micro, and on-chain datasets.
KVDOS Capital

Research &
Analysis

Data-driven insights across life science and biotech markets. Research and analysis to inform strategic planning and capital allocation.

View Reports & Analysis →
KVDOS Capital

Capital
Advisory

Strategic guidance for venture funds deploying capital into biotech and life sciences. Portfolio architecture, deal structuring, and LP advisory for family offices and emerging fund managers focused on therapeutic innovation.

ADV.01
M&A
Strategic M&A advisory across life science and biotech — transaction structuring, target identification, and execution for private companies and portfolio assets.
ADV.02
Portfolio Architecture
Thesis-driven allocation frameworks balancing concentration across therapeutic modalities, vintage risk, and development stage.
ADV.03
Fund Strategy
LP/GP structuring, fund economics, and capital call sequencing for life science-focused emerging managers.
ADV.04
Board Advisory
Governance guidance, clinical development strategy, and exit planning for portfolio companies approaching commercialization.
KVDOS Capital

Private
Capital

Public and private capital deployment across life science and technology. Hedge fund-oriented conviction positions in clinical-stage biotech, platform companies, and event-driven opportunities.

CAP.01
Direct Investment
Concentrated positions in cell therapy, regenerative medicine, and platform biotechnology companies with clear regulatory pathways.
CAP.02
Public Equities
Concentrated long positions in clinical-stage and commercial biotech — conviction-driven positions where deep diligence creates edge in public markets.
CAP.03
Technology Crossover
Public and private positions across health tech, computational biology, and platform infrastructure enabling the next generation of therapeutics.
CAP.04
Hedged Exposure
Long/short and event-driven strategies across biotech catalysts.
Leadership

The Team

Quant & Algo

Loriel L. Director
Marcus R. Lead Analyst
Elena V. Quantitative Research
David K. Sector Analysis
Priya S. Research Analyst
Tomás M. Data Science
Soren A. Algo Strategy
Nadia F. Execution
Oliver T. Systems

Private Capital Advisory

Bryan W. Partner
Harry C. Senior Advisor
Julian P. Advisory
Dominic N. Partner
Camille B. Analyst

Capital

Keith D. Venture Partner
Ava H. Capital
Roman G. Portfolio Ops
Sienna J. Partner
Gabriel E. Analyst

Born from curiosity. Built through determination.

KVDOS Capital team — Himalayas expedition

Contact KVDOS Capital

Email
inquiry@kvdos.capital
Headquarters
1000 Brickell Avenue
Suite #715
Miami, FL 33131

IMPORTANT NOTICE

KVDOS Capital is a private holding company. This website is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities or investment products. Past performance is not indicative of future results.